CSF1R (Colony Stimulating Factor 1 Receptor) Modulation Therapy represents a novel therapeutic strategy that exploits the unique biology of microglia—the brain's resident immune cells. By transiently inhibiting CSF1R signaling, this approach achieves controlled microglia depletion followed by repopulation with phenotypically "reset" microglia, reducing chronic neuroinflammation while preserving essential immune surveillance.[1][2]
This approach differs from complete microglial ablation by incorporating a repopulation phase after transient depletion, allowing for a "reset" of the microglial compartment to a more youthful, less inflammatory phenotype. The therapy is applicable across multiple neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS).
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | Repopulation protocol is novel; inhibitors themselves are known but "reset" strategy is emerging |
| Mechanistic Rationale | 9 | Strong preclinical evidence for microglia reset; CSF1R biology well-validated[4:2][5:3] |
| Addresses Root Cause | 7 | Targets neuroinflammation—a key disease mechanism but not the primary proteinopathy |
| Delivery Feasibility | 7 | Brain-penetrant inhibitors exist (PLX5622, BLZ945); oral delivery possible[6:1] |
| Safety Plausibility | 7 | Known safety profile from oncology; CNS effects need characterization[9] |
| Combinability | 9 | Synergizes with immunotherapy, autophagy inducers, other anti-inflammatory approaches |
| Biomarker Availability | 6 | CSF1, IL-34, TREM2 ligands measurable; microglial imaging in development |
| De-risking Path | 8 | Multiple compounds in clinical trials; established preclinical models[6:2] |
| Multi-disease Potential | 9 | AD, PD, ALS, FTD, MS—all have microglial involvement[7:1][8:1][10] |
| Patient Impact | 8 | Addresses a common pathway across many neurodegenerative conditions |
Total Score: 78/100
| Drug | Company | Stage | CSF1R Selectivity | Notes |
|---|---|---|---|---|
| PLX5622 | Plexxikon | Preclinical | High | Most studied; brain-penetrant[4:3] |
| BLZ945 | Novartis | Preclinical | Very High | Excellent CNS penetration[11] |
| PLX3397 (Pexidartinib) | Plexxikon/Daiichi Sankyo | Phase 1 | Moderate | FDA-approved for TGCT; CNS trials[12] |
| JNJ-40346527 | Janssen | Phase 1 (ALS) | High | Completed safety study[6:3] |
| AXL-2009 | Axxonis | Phase 1 (AD) | High | Currently recruiting |
| Trial ID | Compound | Disease | Phase | Status | Sponsor |
|---|---|---|---|---|---|
| NCT04121247 | JNJ-40346527 | ALS | Phase 1 | Completed | Janssen |
| NCT05452326 | AXL-2009 | AD | Phase 1 | Recruiting | Axxonis |
| NCT04889066 | PLX3397 | Brain Cancer | Phase 1 | Ongoing | Daiichi Sankyo |
| Adverse Event | Frequency | Severity | Management |
|---|---|---|---|
| Liver enzyme elevation | Common | Mild-Moderate | Monitor; reversible on discontinuation |
| Fatigue | Common | Mild | Usually self-limiting |
| Headache | Common | Mild | Self-limiting |
| Anemia | Common | Mild-Moderate | Monitor blood counts |
| Leukopenia | Common | Mild-Moderate | Usually reversible |
| Approach | Mechanism | Stage | Advantages | Limitations |
|---|---|---|---|---|
| CSF1R Modulation | Deplete + reset microglia | Preclinical/Phase 1 | Reversible; phenotypic reset | Requires treatment holiday |
| TREM2 Agonism | Enhance phagocytosis | Preclinical | Direct enhancement of clearance | Single target; less inflammatory |
| CD33 Inhibition | Block inhibitory signal | Preclinical | Oral delivery possible | Limited efficacy alone |
| TREM2 CAR-T | Engineered phagocytes | Preclinical | Targeted cell therapy | Complex delivery |
| Milestone | Timeline | Activities | Lead |
|---|---|---|---|
| Agonist/antagonist comparison | Months 1-4 | Test both approaches in AD/PD mouse models | Academic lab |
| Temporal dosing optimization | Months 3-8 | Determine optimal pulsing schedule | Academic lab |
| IND-enabling studies | Months 6-12 | GLP toxicology for lead compound | CRO |
| Regulatory pre-IND | Months 10-12 | Prepare FDA/EMA package | Regulatory affairs |
Budget Estimate: $3-5M
| Milestone | Timeline | Activities | Lead |
|---|---|---|---|
| Trial design | Months 13-15 | Single ascending dose, healthy volunteers + early AD/PD | Clinical team |
| Site selection | Months 14-16 | Identify 3-4 sites with neuroimaging capabilities | Operations |
| Trial execution | Months 17-24 | Enrollment, dosing, safety monitoring | Sites |
Budget Estimate: $5-8M
| Milestone | Timeline | Activities | Lead |
|---|---|---|---|
| Phase 2 design | Months 25-27 | Biomarker-driven, N=100-150 AD/PD patients | Clinical team |
| Patient enrollment | Months 28-36 | Multi-site enrollment | Sites |
| Data analysis | Months 37-42 | Inflammatory biomarkers, cognitive endpoints | Biostatistics |
Budget Estimate: $15-20M
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Excessive microglial depletion | Medium | High | Test multiple doses, careful monitoring |
| Immune system compromise | Medium | High | Exclude immunocompromised, monitor infections |
| Insufficient target engagement | Medium | Medium | Use PET ligand for occupancy |
| Rebound inflammation | Medium | Medium | Gradual taper, monitor after cessation |
Elmore MR, et al. "Colony-stimulating factor 1 receptor signaling is necessary for microglial survival, proliferation, and function." Nat Neurosci. Nat Neurosci. 2014. ↩︎
Han J, et al. "Microglia repopulation as a therapeutic strategy for neurodegenerative diseases." Trends Neurosci. Trends Neurosci. 2021. ↩︎
Keren-Shaul H, et al. "A unique microglia type associated with Alzheimer's disease." Cell. Cell. 2017. ↩︎
Spangenberg EE, et al. "Sustained microglial depletion with CSF1R inhibitor impairs adult hippocampal neurogenesis." Nat Commun. Nat Commun. 2019. ↩︎ ↩︎ ↩︎ ↩︎
Elmore MR, et al. "Real-time imaging of microglia reveals gold-standard method." Nat Methods. Nat Methods. 2018. ↩︎ ↩︎ ↩︎ ↩︎
ClinicalTrials.gov. "JNJ-40346527 in ALS.". NCT04121247. ↩︎ ↩︎ ↩︎ ↩︎
Dagher NN, et al. "Colony-stimulating factor 1 receptor (CSF1R) inhibition attenuates neuronal loss and improves cognitive function in Alzheimer's disease mouse models." Neuron. Neuron. 2015. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Baruch K, et al. "Targeting CD22 with CD19-directed T-cell immunotherapies." Nat Med. Nat Med. 2015. ↩︎ ↩︎ ↩︎ ↩︎
Martinez-Muriana A, et al. "CSF1R blockade slows disease progression in SOD1G93A mouse model of ALS." Nat Commun. Nat Commun. 2016. ↩︎ ↩︎ ↩︎
Zhou Y, et al. "BLZ945, a highly selective CSF1R inhibitor, demonstrates efficacy in mouse models of Alzheimer's disease." J Neuroinflammation. J Neuroinflammation. 2023. ↩︎ ↩︎
Butowski N, et al. "A phase 1 study of PLX3397 in patients with recurrent glioblastoma." Neuro Oncol. Neuro Oncol. 2016. ↩︎